doi: 10.1016/j.preteyeres.2007.01.004 98
As innovators change their product lifecycle management approach towards increased patient centricity, transitioning from intravenous (IV) infusion to SC administration with an injection device can be a huge game-changer (patient focus, compliance, differentiation from competitors), with notable examples being Herceptin (trastuzumab, Roche/Genentech), MabThera (rituximab, Roche/Genentech), Actemra (tocilizumab, Roche/Genentech), Benlysta (belimumab, GSK), Entyvio (vedolizumab, Takeda) and others
In support of this hypothesis a report by Faure et al
$95.99 - $119.99 You save $55.99 - $69.99 You save $79.99 - $99.99 You save $4.79 - $5.99 You save $23.99 - $29.99 You save $39.99 - $49.99 You save $79.99 - $99.99 You save $63.99 - $79.99 You save Support when you need it
Raw powder is stable at room temperature but lasts longer refrigerated